main-image-avila

Avila Therapeutics

In January 2012 Celgene (NASDAQ: CELG) acquired Avila Therapeutics to pursue development of the company’s Btk inhibitor and covalent drug discovery platform.

Headquarters Bedford, MA
Pipeline Phase 2 Btk program advancing at Celgene